Home/Filings/4/0000914190-12-000124
4//SEC Filing

FRIEDMAN JOHN H 4

Accession 0000914190-12-000124

CIK 0001180145other

Filed

Feb 16, 7:00 PM ET

Accepted

Feb 17, 4:40 PM ET

Size

25.7 KB

Accession

0000914190-12-000124

Insider Transaction Report

Form 4
Period: 2012-02-14
Transactions
  • Sale

    Common Stock

    2012-02-15$8.69/sh52,972$460,3435,853 total(indirect: Easton Hunt Capital Partners, L.P.)
  • Sale

    Common Stock

    2012-02-14$8.82/sh6,850$60,42458,825 total(indirect: Easton Hunt Capital Partners, L.P.)
  • Sale

    Common Stock

    2012-02-16$8.75/sh5,853$51,2180 total(indirect: Easton Hunt Capital Partners, L.P.)
Holdings
  • Common Stock

    (indirect: Easton Capital Partners, LP)
    421,023
  • Stock Option (right to buy)

    Exercise: $7.90Exp: 2017-10-08Common Stock (4,321 underlying)
    4,321
  • Stock Option (right to buy)

    Exercise: $11.38Exp: 2017-11-12Common Stock (15,088 underlying)
    15,088
  • Stock Option (right to buy)

    Exercise: $8.83Exp: 2016-08-14Common Stock (38,820 underlying)
    38,820
  • Restricted Stock Units

    Common Stock (5,714 underlying)
    5,714
  • Restricted Stock Units

    Common Stock (21,739 underlying)
    21,739
  • Warrant (Right to Buy)

    (indirect: Easton Hunt Capital Partners, L.P.)
    Exercise: $9.28From: 2008-09-12Exp: 2013-09-12Common Stock (107,833 underlying)
    107,833
  • Warrant (Right to Buy)

    (indirect: Easton Hunt Capital Partners, L.P.)
    Exercise: $8.83From: 2009-02-25Exp: 2014-02-24Common Stock (151,617 underlying)
    151,617
  • Common Stock

    8,000
  • Restricted Stock Units

    Common Stock (11,628 underlying)
    11,628
  • Restricted Stock Units

    Common Stock (7,192 underlying)
    7,192
  • Warrant (Right to Buy)

    (indirect: Easton Capital Partners, LP)
    Exercise: $8.83From: 2009-02-25Exp: 2014-02-24Common Stock (151,617 underlying)
    151,617
Footnotes (8)
  • [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.89 to $8.80 inclusive. The reporting person undertakes to provide Cardiovascular Systems, Inc., any security holder of Cardiovascular Systems, Inc. or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.65 to $8.78 inclusive. The reporting person undertakes to provide Cardiovascular Systems, Inc., any security holder of Cardiovascular Systems, Inc. or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.70 to $8.87 inclusive. The reporting person undertakes to provide Cardiovascular Systems, Inc., any security holder of Cardiovascular Systems, Inc. or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F4]Mr. Friedman disclaims beneficial ownership of shares held by Easton Hunt Capital Partners, L.P. and Easton Capital Partners, LP except to the extent of his pecuniary interest therein.
  • [F5]Fully exercisable.
  • [F6]Each restricted stock unit represents the right to receive a payment from CSI equal in value to the market price per share of CSI common stock on the date of payment and shall be payable in shares of the Company's Common Stock beginning six months following the termination of each director's board membership.
  • [F7]Each restricted stock unit represents the right to receive a payment from CSI equal in value to the market price per share of CSI common stock on the date of payment, and shall be payable in cash or shares of the Company's Common Stock beginning six months following the termination of each director's board membership; provided, however, that the restricted stock units vest in remaining quarterly amounts of 1,798 on each of 3/31/2012 and 6/30/2012.
  • [F8]Mr. Friedman disclaims beneficial ownership of warrants held by Easton Hunt Capital Partners, L.P. and Easton Capital Partners, LP except to the extent of his pecuniary interest therein.

Issuer

Cardiovascular Systems Inc

CIK 0001180145

Entity typeother

Related Parties

1
  • filerCIK 0001067915

Filing Metadata

Form type
4
Filed
Feb 16, 7:00 PM ET
Accepted
Feb 17, 4:40 PM ET
Size
25.7 KB